<DOC>
	<DOCNO>NCT02647190</DOCNO>
	<brief_summary>The purpose study test safety Erwinia Chrysanthemi asparaginase use alone together chemotherapy find effect , , people .</brief_summary>
	<brief_title>Intravenous Erwinia Chrysanthemi Asparaginase Patients With Newly Diagnosed Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia Aged 60 Years Older</brief_title>
	<detailed_description>The study consist three treatment phase . 1 . Steroid prophase ( day -3 -1 ) : To prevent rapid leukemia progression reduce tumor load , patient receive either prednisone 60mg/m2 oral daily equivalent corticosteroid daily 3 day . 2 . Asparaginase phase ( day 1 - 14 ) : Patients receive Erwinia asparaginase 25,000 IU/m2 IV three time week Monday , Wednesday , Friday ( MWF ) schedule 2 week . Patients permit begin Erwinia asparaginase Monday , Wednesday , Friday , schedule define MWF , WFM , FMW . For rapid progression disease ( define rise WBC &gt; 30K &gt; 50 % peripheral blast ) , prednisone 60mg/m2 oral daily equivalent corticosteroid daily may add . Bone marrow aspirate and/or biopsy perform day 13-15 asparaginase treatment early disease response assessment . 3 . Chemotherapy phase ( day 15 - 42 ) : - Cyclophosphamide 650 mg/m2 IV day 15 - Vincristine 1.4 mg/m2 ( max 2mg ) IV day 15 , 22 , 29 , 36 - Prednisone 60mg/m2 ( equivalent corticosteroid ) oral daily 28 day day 15 - 42 - Erwinia asparaginase 25,000 IU/m2 IV three time week MWF schedule 2 week day 29 - 42 ( two week interval without Erwinia asparaginase administer day 1 - 14 ) Upon cell count recovery , bone marrow aspirate and/or biopsy perform assess disease response . Subsequent treatment follow bone marrow evaluation leave discretion treat physician . If first 6 patient response progress 2 week asparaginase phase treatment without steroid , next 6 patient start directly chemotherapy phase ( day 15-42 ) treatment consist cyclophosphamide , vincristine , prednisone Erwinia asparaginase . CNS prophylaxis : - IT methotrexate 12mg ( flat dose ) day 15 - 22 - IT methotrexate 12mg ( flat dose ) day 22- 29 - There minimal interval dose 7 day</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Philadelphia Chromosome</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<criteria>Ages 60 year old Previously untreated Philadelphia chromosome negative acute lymphoblastic leukemia No prior treatment ALL , except steroid hydroxyurea ( stop within 24 hour start protocol treatment ) Serum creatinine ≤ 2 x upper limit normal ( ULN ) Adequate liver function , include total bilirubin ≤ 1.5 x ULN unless patient document Gilbert syndrome , aspartate alanine aminotransferase ( AST ALT ) ≤ 5 x ULN . If organ function abnormality consider due leukemic infiltration , total bilirubin must ≤ 2 x ULN . ECOG performance status ≤3 Male female patient childbearing potential must agree use highly effective method contraception throughout study minimum 90 day last dose treatment protocol . A patient childbearing potential , opinion investigator , he/she biologically capable child sexually active . Female patient childbearing potential meet least one follow criterion : Have undergone hysterectomy bilateral oophorectomy ; Have medically confirm ovarian failure ; Are medically confirm postmenopausal ( cessation regular menses least 12 consecutive month alternative pathological physiological cause Lymphoblastic crisis CML Mature B cell ( Burkitt 's ) ALL Active central nervous system ( CNS ) leukemia , define unequivocal morphologic evidence lymphoblast cerebrospinal fluid ( CSF ) , use CNSdirected local treatment active disease within prior 28 day , symptomatic CNS leukemia ( i.e. , cranial nerve palsy significant neurologic dysfunction ) within 28 day . Prophylactic intrathecal medication reason exclusion . Pregnant woman woman breastfeed Concurrent active malignancy require immediate therapy Patients human immunodeficiency virus ( HIV )</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Erwinia Chrysanthemi Asparaginase</keyword>
	<keyword>15-107</keyword>
</DOC>